Indirect treatment comparison of durvalumab plus carboplatin/paclitaxel followed by durvalumab plus olaparib versus dostarlimab plus carboplatin/paclitaxel followed by dostarlimab as first-line treatment for mismatch repair proficient endometrial cancer

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Jalid Sehouli, Birutė Brasiūnienė, Marta Gil-Martin, Dagmara Klasa-Mazurkiewicz, Larissa Alejandra Meyer, Kathleen N. Moore, Ayelet Shai, Els Van Nieuwenhuysen, Jack Williams, Abdul-Azeez Ganiyu, Dan James, Zacharie Mbanya
+2 more Marta Vargas Gomes, Shannon Neville Westin
DOI: 10.1016/j.ijgc.2025.104437
Cited by: 0

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments Cancer Immunotherapy and Biomarkers PARP inhibition in cancer therapy

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
104437–104437
Publication date
1 February 2026
Language
EN